[go: up one dir, main page]

MA56019A - NEW COMPOUNDS AND RELATED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES - Google Patents

NEW COMPOUNDS AND RELATED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES

Info

Publication number
MA56019A
MA56019A MA056019A MA56019A MA56019A MA 56019 A MA56019 A MA 56019A MA 056019 A MA056019 A MA 056019A MA 56019 A MA56019 A MA 56019A MA 56019 A MA56019 A MA 56019A
Authority
MA
Morocco
Prior art keywords
diseases
treatment
pharmaceutical compositions
new compounds
related pharmaceutical
Prior art date
Application number
MA056019A
Other languages
French (fr)
Inventor
Luke Jonathan Alvey
Florence Marie-Emilie Bonnaterre
Denis Bucher
Nicolas Desroy
Béranger Duthion
Hélène Marie Jary
Christophe Peixoto
Taoues Temal-Laïb
Amynata Tirera
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MA56019A publication Critical patent/MA56019A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA056019A 2019-05-29 2020-05-25 NEW COMPOUNDS AND RELATED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES MA56019A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1907616.5A GB201907616D0 (en) 2019-05-29 2019-05-29 Novel compounds and pharmaceutical compositons thereof for the treatment of diseases

Publications (1)

Publication Number Publication Date
MA56019A true MA56019A (en) 2022-04-06

Family

ID=67385363

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056019A MA56019A (en) 2019-05-29 2020-05-25 NEW COMPOUNDS AND RELATED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES

Country Status (26)

Country Link
US (1) US12391679B2 (en)
EP (1) EP3976189B1 (en)
JP (1) JP7550174B2 (en)
KR (1) KR20220015450A (en)
CN (1) CN113924146B (en)
AR (1) AR119028A1 (en)
AU (1) AU2020281650B2 (en)
BR (1) BR112021023900A2 (en)
CA (1) CA3141683A1 (en)
CL (1) CL2021003133A1 (en)
CO (1) CO2021017656A2 (en)
CR (1) CR20210586A (en)
DO (1) DOP2021000227A (en)
EA (1) EA202193281A1 (en)
ES (1) ES2985528T3 (en)
GB (1) GB201907616D0 (en)
IL (1) IL288375B1 (en)
MA (1) MA56019A (en)
MX (1) MX2021013803A (en)
PE (1) PE20220503A1 (en)
PH (1) PH12021552691A1 (en)
PL (1) PL3976189T3 (en)
SG (1) SG11202112652RA (en)
TW (1) TW202110839A (en)
WO (1) WO2020239658A1 (en)
ZA (1) ZA202110597B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018053373A1 (en) 2016-09-16 2018-03-22 The General Hospital Corporation Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis
CA3129019A1 (en) 2019-03-11 2020-09-17 Yong Li Fused piperidinyl bicyclic and related compounds as modulators of c5a receptor
GB201907558D0 (en) * 2019-05-29 2019-07-10 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
WO2022031928A1 (en) * 2020-08-05 2022-02-10 The General Hospital Corporation Salt inducible kinase inhibitors
USD982434S1 (en) * 2021-08-31 2023-04-04 Level Up Dice LLC Dice storage container
CN118119619A (en) * 2021-10-18 2024-05-31 上海美悦生物科技发展有限公司 SIK inhibitor and composition, preparation method and application thereof
AR128279A1 (en) * 2022-01-19 2024-04-10 Hoffmann La Roche NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES
CN115304605B (en) * 2022-01-21 2023-10-03 陕西国际商贸学院 Oxetane derivatives with antitumor activity, and preparation method and application thereof
WO2024003209A1 (en) * 2022-07-01 2024-01-04 F. Hoffmann-La Roche Ag Imidazo[4,5-c]pyridine derivatives as sik modulators for the treatment of rheumatoid arthritis
US20240124450A1 (en) * 2022-09-21 2024-04-18 Pfizer Inc. Novel SIK Inhibitors
EP4619397A1 (en) * 2022-11-17 2025-09-24 Insilico Medicine IP Limited Salt-inducible kinases (sik) inhibitors and methods of uses thereof
WO2024242169A1 (en) * 2023-05-24 2024-11-28 田辺三菱製薬株式会社 Salt-inducible kinase inhibitory compound and pharmaceutical composition containing same
CN116813608B (en) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 Thiazole compound and application thereof
TW202517630A (en) * 2023-07-19 2025-05-01 瑞士商赫孚孟拉羅股份公司 New benzimidazole pyridine derivatives
WO2025068090A1 (en) * 2023-09-26 2025-04-03 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of diseases
WO2025232877A1 (en) * 2024-05-10 2025-11-13 Insilico Medicine Ip Limited Salt-inducible kinases (sik) inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461162B2 (en) 2007-07-20 2013-06-11 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidine derivatives
JP6261340B2 (en) 2010-11-18 2018-01-17 リガンド ファーマシューティカルズ インコーポレイテッド Use of hematopoietic growth factor mimics
JP6171149B2 (en) 2010-12-01 2017-08-02 プレイザン カーボン コンポジティーズ,インコーポレイテッド Method and system for forming composite articles
US9512126B2 (en) 2012-03-14 2016-12-06 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
US9260426B2 (en) * 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
US10730842B2 (en) 2015-09-03 2020-08-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof
CN106496222A (en) 2016-09-07 2017-03-15 华东师范大学 A kind of imidazo [1,2 a] pyridine compounds and its preparation method and application
SG11202004925QA (en) 2017-12-02 2020-06-29 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
CN108358894B (en) * 2018-04-26 2021-05-07 四川大学 Compound for inhibiting histone acetyltransferase as well as preparation method and application thereof
CA3103304A1 (en) 2018-06-15 2019-12-19 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
CN118684661A (en) 2023-03-21 2024-09-24 上海美悦生物科技发展有限公司 Heteroaryl compounds and pharmaceutical compositions, preparation methods and uses thereof

Also Published As

Publication number Publication date
SG11202112652RA (en) 2021-12-30
TW202110839A (en) 2021-03-16
CN113924146B (en) 2024-12-10
PE20220503A1 (en) 2022-04-07
JP7550174B2 (en) 2024-09-12
JP2022534578A (en) 2022-08-02
DOP2021000227A (en) 2022-05-15
AU2020281650B2 (en) 2025-08-28
EP3976189C0 (en) 2024-07-03
MX2021013803A (en) 2021-12-14
EP3976189B1 (en) 2024-07-03
AU2020281650A1 (en) 2022-02-03
CR20210586A (en) 2022-01-24
ES2985528T3 (en) 2024-11-06
WO2020239658A1 (en) 2020-12-03
PH12021552691A1 (en) 2022-03-14
PL3976189T3 (en) 2024-09-09
CA3141683A1 (en) 2020-12-03
EA202193281A1 (en) 2022-03-01
CL2021003133A1 (en) 2022-07-22
IL288375B1 (en) 2025-09-01
CO2021017656A2 (en) 2022-01-17
BR112021023900A2 (en) 2022-01-18
GB201907616D0 (en) 2019-07-10
US12391679B2 (en) 2025-08-19
KR20220015450A (en) 2022-02-08
ZA202110597B (en) 2024-10-30
EP3976189A1 (en) 2022-04-06
US20220340548A1 (en) 2022-10-27
CN113924146A (en) 2022-01-11
IL288375A (en) 2022-01-01
AR119028A1 (en) 2021-11-17

Similar Documents

Publication Publication Date Title
MA56019A (en) NEW COMPOUNDS AND RELATED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES
MA51200A (en) NEW COMPOUNDS AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES
MA52873A (en) NEW COMPOUNDS AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES
MA51739A (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS
MA55325A (en) COMPOUNDS FOR THE TREATMENT OF PD-L1 DISEASES
MA50391A (en) NEW COMPOUNDS AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
EP3866781A4 (en) NEW COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISEASES
MA52118A (en) NEW COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS
EP3704108A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF BLOOD DISORDERS
EP4045036A4 (en) HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1-ASSOCIATED DISEASES
EP3937932A4 (en) CGAZ INHIBITORS FOR THE TREATMENT OF AUTOINFLAMMATORY DISEASES AND CANCER METASTASIS
EP3890747A4 (en) COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND INFLAMMATION
MA51524A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES INVOLVING ACIDIC OR HYPOXIC DISEASE TISSUES
EP3841086A4 (en) PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS
EP3661553A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOID DEPOSITED DISEASES
MA50905A (en) COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF FIBROTIC DISEASES
EP3946357A4 (en) TOPICAL FORMULATIONS FOR THE TREATMENT OF PERIPHERAL NEUROPATHIES
EP3639833A4 (en) AGENT FOR THE PREVENTION OR TREATMENT OF DISEASES RELATED TO FAT AND / OR INFLAMMATION
EP3328864A4 (en) COMPOUNDS AND THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF SOCIAL DISORDERS AND ADDICTION-RELATED DISORDERS
MA53614A (en) PROTEIN FOR THE TREATMENT OF INFLAMMATORY DISEASES
MA55982A (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMORS
EP3936124A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL DISEASES
EP4209216A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMORS
EP3919052A4 (en) PHARMACEUTICAL COMPOSITION FOR INTRAOCULAR OR ORAL ADMINISTRATION FOR THE TREATMENT OF RETINAL DISEASES
EP3960858A4 (en) SMALL RNA MEDICINE FOR THE PREVENTION AND TREATMENT OF INFLAMMATION RELATED DISEASES AND THEIR COMBINATION